Tonix Pharmaceuticals Holding Corp (TNXP)

[mick]

$TNXP Tonix’s lead vaccine candidate, TNX-1800*, is a live replicating, attenuated vaccine based on the horsepox viral vector platform to protect against COVID-19, primarily by eliciting a T cell response.

Tonix expects data from animal studies of TNX-1800 in the fourth quarter of this year.

TNX-801*, live horsepox virus vaccine for percutaneous administration, is in development to protect against smallpox and monkeypox and serves as the vector platform on which TNX-1800 is based.

Tonix is also developing TNX-2300* and TNX-2600*, live replicating vaccine candidates for the prevention of COVID-19, but using bovine parainfluenza as the vector.

Tonix’s lead CNS candidate, TNX-102 SL**, is in Phase 3 development for the management of fibromyalgia.